67°

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Akebia Therapeutics, Inc. - Common Stock (NQ:AKBA)

0.9101 -0.0144 (-1.56%)

Streaming Delayed Price Updated: 2:20 PM EDT, Jun 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akebia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

AKEBIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm

May 11, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 10, 2022

Via Benzinga

NASDAQ:AKBA Investor Notice: Deadline on May 13, 2022 in Lawsuit Against Akebia Therapeutics, Inc. ↗

May 10, 2022

San Diego, CA -- (SBWIRE) -- 05/10/2022 -- The Shareholders Foundation announced that a deadline is coming up on May 13, 2022 in the lawsuit filed for certain investors of Akebia Therapeutics, Inc....

Via SBWire

AKBA FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - AKBA

May 09, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Stocks That Hit 52-Week Lows On Friday ↗

April 08, 2022

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap...

Via Benzinga

FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff ↗

April 07, 2022

Via Benzinga

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia ↗

March 30, 2022

Via Benzinga

103 Biggest Movers From Yesterday ↗

May 11, 2022

Gainers

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages May 13, 2022 Deadline

May 09, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBA

April 30, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

April 26, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

AKBA INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

April 24, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

April 15, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

April 09, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

See Why Does HC Wainwright Maintain Neutral On Akebia Stock ↗

April 07, 2022

Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

April 04, 2022

On Monday, 78 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: Citigroup (NYSE:C) was the biggest company by market cap to set a new 52-week low....

Via Benzinga

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action AKBA

April 02, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

53 Biggest Movers From Yesterday ↗

April 01, 2022

Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 01, 2022

On Friday, 111 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Citigroup (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022 ↗

March 31, 2022

Upgrades

Via Benzinga

6 Stocks Halted In Wednesday's Session ↗

March 30, 2022

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 30, 2022

Gainers Adagio Therapeutics (NASDAQ:ADGI) shares rose 40.0% to $5.39 during Wednesday's regular session. Trading volume for this security as of 13:31 EST is 80.0...

Via Benzinga

51 Biggest Movers From Yesterday ↗

March 31, 2022

Gainers Forge Global Holdings, Inc. (NYSE: FRGE) jumped 73.9% to close at $37.64. Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 60.5% to close at $4.14 on Wednesday...

Via Benzinga

NASDAQ:AKBA Investor Notice: Lawsuit Alleges Securities Laws Violations by Akebia Therapeutics, Inc. ↗

March 30, 2022

San Diego, CA -- (SBWIRE) -- 03/30/2022 -- An investor, who purchased shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA), filed a lawsuit over alleged violations of Federal Securities Laws by Akebia...

Via SBWire

35 Stocks Moving In Wednesday's Mid-Day Session ↗

March 30, 2022

Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares jumped 82.6% to $4.71 after the company reported a year over year increase in Q4 sales results and issued Q1 sales...

Via Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm

March 22, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Akebia Therapeutics, Inc. - Common Stock (NQ:AKBA)

All News about Akebia Therapeutics, Inc. - Common Stock

Sections

Services